These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1001 related articles for article (PubMed ID: 15963307)

  • 1. Cholesterol levels and statin use in patients with coronary heart disease treated in primary care settings.
    O'Connor PJ; Gray RJ; Maciosek MV; Fillbrandt KM; DeFor TA; Alexander CM; Weiss TW; Teutsch SM
    Prev Chronic Dis; 2005 Jul; 2(3):A05. PubMed ID: 15963307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.
    Wong ND; Chuang J; Zhao Y; Rosenblit PD
    J Clin Lipidol; 2015; 9(4):525-32. PubMed ID: 26228670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholesterol efflux and metabolic abnormalities associated with low high-density-lipoprotein-cholesterol and high triglycerides in statin-treated coronary men with low-density lipoprotein-cholesterol <70 mg/dl.
    Posadas-Sánchez R; Posadas-Romero C; Mendoza-Pérez E; Caracas-Portilla NA; Cardoso-Saldaña G; Medina-Urrutia A; Jorge-Galarza E; Juárez-Rojas JG
    Am J Cardiol; 2012 Mar; 109(5):636-41. PubMed ID: 22169129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol.
    Alsheikh-Ali AA; Lin JL; Abourjaily P; Ahearn D; Kuvin JT; Karas RH
    Am J Cardiol; 2007 Nov; 100(10):1499-501. PubMed ID: 17996508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HMG-CoA reductase inhibitor (Statin) therapy and coronary atherosclerosis in Japanese subjects: role of high-density lipoprotein cholesterol.
    Tani S; Nagao K; Hirayama A
    Am J Cardiovasc Drugs; 2011 Dec; 11(6):411-7. PubMed ID: 22149320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Magnitude and characteristics of residual lipid risk in patients with a history of coronary revascularization: the ICP-bypass study].
    González-Juanatey JR; Cordero A; Vitale GC; González-Timón B; Mazón P; Bertomeu V
    Rev Esp Cardiol; 2011 Oct; 64(10):862-8. PubMed ID: 21835533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis.
    Nicholls SJ; Tuzcu EM; Sipahi I; Grasso AW; Schoenhagen P; Hu T; Wolski K; Crowe T; Desai MY; Hazen SL; Kapadia SR; Nissen SE
    JAMA; 2007 Feb; 297(5):499-508. PubMed ID: 17284700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment pattern changes in high-risk patients newly initiated on statin monotherapy in a managed care setting.
    Simpson RJ; Tunceli K; Ramey DR; Neff DR; Kern DM; Hsieh HM; Wertz DA; Stephenson JJ; Marrett E; Tomassini JE; Jacobson TA
    J Clin Lipidol; 2013; 7(5):399-407. PubMed ID: 24079280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: a retrospective analysis.
    Jones PH; Nair R; Thakker KM
    J Am Heart Assoc; 2012 Dec; 1(6):e001800. PubMed ID: 23316314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels.
    Querton L; Buysschaert M; Hermans MP
    J Clin Lipidol; 2012; 6(5):434-42. PubMed ID: 23009779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
    Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
    Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Individualized Risk Communication and Outreach for Primary Cardiovascular Disease Prevention in Community Health Centers: Randomized Trial.
    Persell SD; Brown T; Lee JY; Shah S; Henley E; Long T; Luther S; Lloyd-Jones DM; Jean-Jacques M; Kandula NR; Sanchez T; Baker DW
    Circ Cardiovasc Qual Outcomes; 2015 Nov; 8(6):560-6. PubMed ID: 26555123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic Dyslipidemia and Risk of Coronary Heart Disease in 28,318 Adults With Diabetes Mellitus and Low-Density Lipoprotein Cholesterol <100 mg/dl.
    Rana JS; Liu JY; Moffet HH; Solomon MD; Go AS; Jaffe MG; Karter AJ
    Am J Cardiol; 2015 Dec; 116(11):1700-4. PubMed ID: 26428026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries--Findings from the EUROASPIRE IV survey.
    Reiner Ž; De Backer G; Fras Z; Kotseva K; Tokgözoglu L; Wood D; De Bacquer D;
    Atherosclerosis; 2016 Mar; 246():243-50. PubMed ID: 26812002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of statin-ezetimibe combination to reduce the care gap in dyslipidemia management in patients with a high risk of atherosclerotic disease.
    Teoh H; Mendelsohn AA; Goodman SG; Jaffer S; Chen RY; Tjia S; Theriault L; Langer A; Leiter LA;
    Am J Cardiol; 2009 Sep; 104(6):798-804. PubMed ID: 19733714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency of Attainment of Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol Goals in Cardiovascular Clinical Practice (from the National Cardiovascular Data Registry PINNACLE Registry).
    Spinler SA; Cziraky MJ; Willey VJ; Tang F; Maddox TM; Thomas T; Dueñas GG; Virani SS;
    Am J Cardiol; 2015 Aug; 116(4):547-53. PubMed ID: 26089010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequency of obtaining national cholesterol education program adult treatment panel III goals for all major serum lipoproteins after initiation of lipid altering therapy.
    Nichols GA; Ambegaonkar BM; Sazonov V; Brown JB
    Am J Cardiol; 2009 Dec; 104(12):1689-94. PubMed ID: 19962476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE; Feely J; Sigurdsson EL;
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: Results from the Dyslipidemia International Study II.
    Gitt AK; Lautsch D; Ferrières J; De Ferrari GM; Vyas A; Baxter CA; Bash LD; Ashton V; Horack M; Almahmeed W; Chiang FT; Poh KK; Brudi P; Ambegaonkar B
    Atherosclerosis; 2017 Nov; 266():158-166. PubMed ID: 29028484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.